European journal of clinical investigation
-
Eur. J. Clin. Invest. · Apr 2012
Randomized Controlled TrialJustification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
The GRAVITAS trial showed that 150 mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150 mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA). ⋯ One-month administration of 150 mg maintenance dose of clopidogrel reduces platelet reactivity and might decrease the risk of thrombo-ischaemic complications in stable angina patients with HPR identified by LTA.